FindMyKOL
Clinical trialNCT05188170RecruitingPhase 1Interventional

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

SponsorStanford UniversityEnrollment16Acute Myeloid Leukemia (AML)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stanford University

    Palo Alto, California, United States

    Adam Frymoyer, MDJennifer Kamens, M.DKathleen Sakamoto, M.D., Ph.DNamrata Patel, PharmDNorman Lacayo, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Niclosamide
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Nov 2022
Primary completion
30 Sept 2026
Completion
31 Dec 2026
Last update posted
12 Aug 2026
Registered enrollment
16
Registry id
NCT05188170
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.